DK1357901T3 - Fremgangsmåde til fremstilling af partikler - Google Patents

Fremgangsmåde til fremstilling af partikler

Info

Publication number
DK1357901T3
DK1357901T3 DK02715546T DK02715546T DK1357901T3 DK 1357901 T3 DK1357901 T3 DK 1357901T3 DK 02715546 T DK02715546 T DK 02715546T DK 02715546 T DK02715546 T DK 02715546T DK 1357901 T3 DK1357901 T3 DK 1357901T3
Authority
DK
Denmark
Prior art keywords
liquid
particles
temperature
substance
modulator
Prior art date
Application number
DK02715546T
Other languages
Danish (da)
English (en)
Inventor
Goran Eric Sundholm
Mustafa Demirbuker
Saeed Moshashaee
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1357901T3 publication Critical patent/DK1357901T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK02715546T 2001-01-26 2002-01-22 Fremgangsmåde til fremstilling af partikler DK1357901T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0102075.9A GB0102075D0 (en) 2001-01-26 2001-01-26 Process
PCT/GB2002/000261 WO2002058674A2 (fr) 2001-01-26 2002-01-22 Procede

Publications (1)

Publication Number Publication Date
DK1357901T3 true DK1357901T3 (da) 2007-06-04

Family

ID=9907591

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02715546T DK1357901T3 (da) 2001-01-26 2002-01-22 Fremgangsmåde til fremstilling af partikler

Country Status (22)

Country Link
US (2) US7108867B2 (fr)
EP (1) EP1357901B1 (fr)
JP (1) JP4175892B2 (fr)
KR (1) KR100853596B1 (fr)
CN (1) CN1298312C (fr)
AT (1) ATE354352T1 (fr)
BR (1) BR0206439A (fr)
CA (1) CA2433838A1 (fr)
CY (1) CY1106550T1 (fr)
DE (1) DE60218285T2 (fr)
DK (1) DK1357901T3 (fr)
ES (1) ES2281509T3 (fr)
GB (1) GB0102075D0 (fr)
HK (1) HK1063157A1 (fr)
IL (2) IL156720A0 (fr)
MX (1) MXPA03006537A (fr)
NO (1) NO20033241D0 (fr)
NZ (1) NZ526942A (fr)
PT (1) PT1357901E (fr)
SI (1) SI1357901T1 (fr)
WO (1) WO2002058674A2 (fr)
ZA (1) ZA200304953B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
GB0126716D0 (en) * 2001-11-07 2002-01-02 Advanced Phytonics Ltd Method for the production of particles
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
AU2003297367A1 (en) * 2002-12-19 2004-07-14 Baxter International, Inc. Process for preparing pharmaceutical formulations using supercritical fluids
AU2004234057A1 (en) * 2003-04-29 2004-11-11 Akzo Nobel N.V. Antisolvent solidification process
EP1624862B1 (fr) 2003-05-08 2014-12-31 Nektar Therapeutics Materiaux particulaires
WO2005032511A2 (fr) * 2003-09-30 2005-04-14 Spherics, Inc. Agents therapeutiques nanoparticulaires biologiquement actifs
US7220456B2 (en) 2004-03-31 2007-05-22 Eastman Kodak Company Process for the selective deposition of particulate material
US7223445B2 (en) 2004-03-31 2007-05-29 Eastman Kodak Company Process for the deposition of uniform layer of particulate material
EP1904219A4 (fr) * 2005-07-15 2011-07-27 Map Pharmaceuticals Inc Procede de formation de particules
NL1031224C2 (nl) * 2006-02-23 2007-09-03 Friesland Brands Bv Het bereiden van gedroogde deeltjes met behulp van een superkritisch medium.
CA2677532A1 (fr) * 2007-02-06 2008-08-14 Incept, Llc Polymerisation avec precipitation de proteines pour elution dans une solution physiologique
EP2120875B1 (fr) 2007-02-11 2018-07-11 Map Pharmaceuticals Inc. Procédé d'administration thérapeutique de dhe pour procurer un soulagement rapide de la migraine tout en minimisant le profil des effets secondaires
JP5307382B2 (ja) * 2007-11-14 2013-10-02 日機装株式会社 微粒子化方法
JP2011507676A (ja) * 2007-12-07 2011-03-10 エクスプレイ ミクロパーティクルズ アクティエボラーグ 粒子を生成する方法と構造
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition
MY171146A (en) * 2012-03-22 2019-09-27 Novo Nordisk As Compositions of glp-1 peptides and preparation thereof
JP6668652B2 (ja) 2015-09-18 2020-03-18 日本精工株式会社 直動案内装置、直動案内装置用エンドキャップ

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69005800T2 (de) 1989-05-01 1994-05-19 Alkermes Inc Verfahren zur herstellung von kleinen partikeln von biologisch aktiven molekülen.
US5639441A (en) 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
GB9313642D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US6576264B1 (en) 1995-10-17 2003-06-10 Skyepharma Canada Inc. Insoluble drug delivery
GB9703673D0 (en) 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
GB9804379D0 (en) 1998-03-02 1998-04-22 Bradford Particle Design Ltd Method of particle formation
EP1071402B1 (fr) 1998-04-09 2006-09-13 F. Hoffmann-La Roche Ag Procede de production de particules submicroniques par dissolution dans du gaz comprime et des tensioactifs
SE9801287D0 (sv) 1998-04-14 1998-04-14 Astra Ab Incorporation of active substances in carrier matrixes
GB9810559D0 (en) 1998-05-15 1998-07-15 Bradford Particle Design Ltd Method and apparatus for particle formation
SE9804001D0 (sv) 1998-11-23 1998-11-23 Astra Ab New process
GB9828204D0 (en) 1998-12-21 1999-02-17 Smithkline Beecham Plc Process
GB9915975D0 (en) 1999-07-07 1999-09-08 Bradford Particle Design Ltd Method for the formation of particles
GB9920558D0 (en) 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
JP2004534900A (ja) * 2001-07-12 2004-11-18 イーストマン コダック カンパニー 圧縮流体配合物
US6998051B2 (en) * 2002-07-03 2006-02-14 Ferro Corporation Particles from supercritical fluid extraction of emulsion
WO2005055983A2 (fr) * 2003-12-09 2005-06-23 Medcrystalforms, Llc Procede de preparation de cocristaux a phase mixte avec des agents actifs
US7754243B2 (en) * 2004-08-03 2010-07-13 Clemson University Research Foundation Aqueous suspension of nanoscale drug particles from supercritical fluid processing

Also Published As

Publication number Publication date
DE60218285D1 (de) 2007-04-05
WO2002058674A2 (fr) 2002-08-01
DE60218285T2 (de) 2007-11-15
CN1487825A (zh) 2004-04-07
CY1106550T1 (el) 2012-01-25
CA2433838A1 (fr) 2002-08-01
CN1298312C (zh) 2007-02-07
BR0206439A (pt) 2003-12-30
NZ526942A (en) 2005-04-29
US7108867B2 (en) 2006-09-19
MXPA03006537A (es) 2003-09-22
KR20030070921A (ko) 2003-09-02
IL156720A (en) 2010-03-28
EP1357901B1 (fr) 2007-02-21
PT1357901E (pt) 2007-05-31
WO2002058674A3 (fr) 2002-11-21
KR100853596B1 (ko) 2008-08-22
NO20033241L (no) 2003-07-17
US20070009604A1 (en) 2007-01-11
NO20033241D0 (no) 2003-07-17
SI1357901T1 (sl) 2007-08-31
EP1357901A2 (fr) 2003-11-05
US7829123B2 (en) 2010-11-09
ZA200304953B (en) 2004-08-25
GB0102075D0 (en) 2001-03-14
AU2002225193B2 (en) 2006-07-27
ES2281509T3 (es) 2007-10-01
JP2004521891A (ja) 2004-07-22
HK1063157A1 (en) 2004-12-17
IL156720A0 (en) 2004-01-04
JP4175892B2 (ja) 2008-11-05
ATE354352T1 (de) 2007-03-15
US20040058007A1 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
DK1357901T3 (da) Fremgangsmåde til fremstilling af partikler
ATE478107T1 (de) Verfahren zur reinigung von polyetherketone mit wasser
Geiser et al. In-line system containing porous polymer monoliths for protein digestion with immobilized pepsin, peptide preconcentration and nano-liquid chromatography separation coupled to electrospray ionization mass spectroscopy
BRPI0315652B8 (pt) molécula de ácido nucleico isolada, vetor, polipeptídeo de fusão, e, multímero
ATE541919T1 (de) Herstellung eines proteins in serumfreier zellkultur, die ein proteinhydrolysat aus pflanzen enthält
EA200501263A1 (ru) Удаление загрязнителей из природного газа с помощью охлаждения
BR0304937B1 (pt) composição de antiespumante de silicone encapsulado e processo para a produção de uma composição de antiespumante de silicone encapsulado.
NO20055607L (no) Antilosemiddel solidifiseringsprosess
DK1528953T3 (da) Fremgangsmåde og anordning til stripning af ammoniak fra væsker
NZ332835A (en) Deacidifying hydrocarbon containing gas by contacting with solvent under temperature gradient
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
CN105566671A (zh) 一种制备有机-无机杂化多孔整体材料的方法
ATE336589T1 (de) Deesterifizierte pectine, verfahren zur herstellung von diesen, und diese enthaltende stabilisierte saure flüssigkeitssysteme
ATE365801T1 (de) Modulierung durch il-tif/interleukin-21
DE60124419D1 (de) Glasreaktion via flüssigkeitsverkapselung
DK1465663T3 (da) Brugsfærdige paracetamol-injektionsoplösninger som indeholder propylenglycol som det eneste CO-oplösningsmiddel
ATE551991T1 (de) Formulierung aus feinen teilchen mit verflüssigten oder dichten gasen
DE60203287D1 (de) Verfahren zur erhitzung und doppelten elektromagnetischen polarisation von flüssigem und gasförmigem brennstoff und dazugehörige vorrichtung
ATE374824T1 (de) Lösliche notch basierte substrate für gamma secretase, methoden, zusammensetzungen und verwendungen davon
ATE316575T1 (de) Rekombinante mistellektine
ATE498646T1 (de) Verfahren zur herstellung von mikropartikeln
SE0002364D0 (sv) Growth Factors
WO2004020983A3 (fr) Dispositif d'ultrafiltration pour des etudes de liaison de medicaments
Massis Biophysical studies and thermodynamic analysis of cathepsin B interactions
KR890701754A (ko) 정제된 인돌 수용액의 제조방법